Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 1;14(1):e2022016.
doi: 10.4084/mjhid.2022.016. eCollection 2022.

Immunological Evolution of a Cohort of HIV-2 Infected Patients: Peculiarities of an Underestimated Infection

Benedetta Fumarola  1   2 , Stefano Calza  3 , Stefano Renzetti  3 , Issa El Hamad  1 , Maria C Pezzoli  1 , Ilaria Izzo  1 , Melania Degli Antoni  1   2 , Annacarla Chiesa  1   2 , Maria De Francesco  4 , Eugenia Quiros-Roldan  1   2 , Arnaldo Caruso  4 , Francesco Castelli  1   2 , Emanuele Focà  1   2
Affiliations

Immunological Evolution of a Cohort of HIV-2 Infected Patients: Peculiarities of an Underestimated Infection

Benedetta Fumarola et al. Mediterr J Hematol Infect Dis. .

Abstract

Background: Human Immunodeficiency Virus type 2 (HIV-2) affects a minority of patients in Italy; nevertheless, the increasing migratory flow from higher prevalence areas led to the spread of this virus into our Country. We evaluate clinical, viro-immunological, and therapeutic characteristics of patients with HIV-2 infection and HIV-1/HIV-2 dual-infection and the early treatment impact on overall survival and incidence of AIDS events.

Methods: We retrospectively analyzed all HIV-2, and HIV-1/HIV-2 positive patients followed in a large Italian clinic from January 1987 to December 2020. We recorded demographic, viro-immunological, clinical, and therapeutic data. We performed a descriptive analysis followed by a longitudinal analysis to explore the factors associated with the CD4+ lymphocyte trend; lastly, we studied the possible predictors of death and AIDS in our cohort in a multivariable model.

Results: 32 subjects were enrolled, 17 (53%) HIV-2 infected and 15 (46.8%) HIV-1/HIV-2 dual-infected; 12 patients were lost to follow up, while 3 died. We found a lack of HIV-2 viremia in 12/32 subjects (37.5%). Most of the patients at baseline had a good viro-immunological profile with HIV-2 RNA <200 copies/ml and CD4+ lymphocyte >200 cell/mcl. We found a CD4+ lymphocyte improvement over time, both in the absolute number (β 472.61, 95%CI 383.05-562.18, p<0.001) and in percentage (β 25.28, 95%CI 21.91 - 28.66, p<0.001). Nevertheless, subjects taking cART had CD4+ lymphocyte percentage increase over time, and this trend appeared significantly better than those who did not receive therapy. Lastly, in the multivariable model CD4+, T-cell count increase was negatively associated with AIDS (HR 0.34 95%CI 0.13-0.91, p=0.032).

Conclusion: We found a higher prevalence of HIV-1/2 dual infection than in previous observations. Subjects with HIV-2 infection showed a favorable immunological condition at diagnosis, and the benefits of cART in those who received treatment are undiscussed. Moreover, our data suggest a different disease course based on age at diagnosis, as in HIV-1 infections. We encourage starting cART at diagnosis in HIV-2 patients, regardless of CD4+ lymphocyte, because even in the new cART era, CD4+ lymphocyte decrease remains the strongest predictor of death and AIDS also in this population.

Keywords: AIDS; HIV-1; HIV-2; Italy; cART.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no conflict of Interest.

Figures

Figure 1
Figure 1
CD4 lymphocytes trend in cART-naive and in cART-experienced patients.
See this image and copyright information in PMC

References

    1. UNAIDS. [Accessed on July 15, 2020]. http://www.unaids.org/en/
    1. Gao F, Yue L, White AT, Pappas PG, Barchue J, Hanson AP, et al. Human infection by genetically diverse SIVSM-related HIV-2 in West Africa. Nature. 1992;358(6386):495–9. doi: 10.1038/358495a0. - DOI - PubMed
    1. Gao F, Yue L, Robertson DL, Hill SC, Hui H, Biggar RJ, et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol. 1994;68(11) doi: 10.1128/jvi.68.11.7433-7447.1994. - DOI - PMC - PubMed
    1. Ayouba A, Akoua-Koffi C, Calvignac-Spencer S, Esteban A, Locatelli S, Li H, et al. Evidence for continuing cross-species transmission of SIVsmm to humans: Characterization of a new HIV-2 lineage in rural Côte d‘Ivoire. AIDS. 2013;27(15):2488–91. doi: 10.1097/01.aids.0000432443.22684.50. - DOI - PMC - PubMed
    1. Santiago ML, Range F, Keele BF, Li Y, Bailes E, Bibollet-Ruche F, et al. Simian Immunodeficiency Virus Infection in Free-Ranging Sooty Mangabeys (Cercocebus atys atys) from the Taï Forest, Côte d‘Ivoire: Implications for the Origin of Epidemic Human Immunodeficiency Virus Type 2. J Virol. 2005;79(19):12515–27. doi: 10.1128/JVI.79.19.12515-12527.2005. - DOI - PMC - PubMed